New monoclonal antibodies for hematologic malignancies (and breast cancer).
Curtis
Mark A
MA
Department of Pharmacy, Roger Williams Medical Center, 825 Chalkstone Avenue, Providence, RI 02908, USA. mcurtis@rwmc.org
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D004167:Diphtheria Toxin / Q000627:therapeutic use; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D000069283:Rituximab; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D004167:Diphtheria Toxin; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; C078456:denileukin diftitox; D000074323:Alemtuzumab; D000069283:Rituximab; D000068878:Trastuzumab